S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   176.29 (+0.71%)
MSFT   423.74 (-0.98%)
META   514.83 (-1.59%)
GOOGL   159.67 (+0.16%)
AMZN   187.89 (-0.61%)
TSLA   172.49 (-1.21%)
NVDA   889.35 (-1.86%)
AMD   163.50 (-4.11%)
NIO   4.26 (-4.48%)
BABA   72.65 (-2.94%)
T   16.44 (+0.12%)
F   12.86 (-1.38%)
MU   124.65 (-2.24%)
GE   155.82 (-1.00%)
CGC   8.36 (+2.58%)
DIS   115.99 (-0.99%)
AMC   2.75 (-1.79%)
PFE   26.30 (-0.15%)
PYPL   65.52 (-0.43%)
XOM   123.26 (+1.21%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   176.29 (+0.71%)
MSFT   423.74 (-0.98%)
META   514.83 (-1.59%)
GOOGL   159.67 (+0.16%)
AMZN   187.89 (-0.61%)
TSLA   172.49 (-1.21%)
NVDA   889.35 (-1.86%)
AMD   163.50 (-4.11%)
NIO   4.26 (-4.48%)
BABA   72.65 (-2.94%)
T   16.44 (+0.12%)
F   12.86 (-1.38%)
MU   124.65 (-2.24%)
GE   155.82 (-1.00%)
CGC   8.36 (+2.58%)
DIS   115.99 (-0.99%)
AMC   2.75 (-1.79%)
PFE   26.30 (-0.15%)
PYPL   65.52 (-0.43%)
XOM   123.26 (+1.21%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   176.29 (+0.71%)
MSFT   423.74 (-0.98%)
META   514.83 (-1.59%)
GOOGL   159.67 (+0.16%)
AMZN   187.89 (-0.61%)
TSLA   172.49 (-1.21%)
NVDA   889.35 (-1.86%)
AMD   163.50 (-4.11%)
NIO   4.26 (-4.48%)
BABA   72.65 (-2.94%)
T   16.44 (+0.12%)
F   12.86 (-1.38%)
MU   124.65 (-2.24%)
GE   155.82 (-1.00%)
CGC   8.36 (+2.58%)
DIS   115.99 (-0.99%)
AMC   2.75 (-1.79%)
PFE   26.30 (-0.15%)
PYPL   65.52 (-0.43%)
XOM   123.26 (+1.21%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   176.29 (+0.71%)
MSFT   423.74 (-0.98%)
META   514.83 (-1.59%)
GOOGL   159.67 (+0.16%)
AMZN   187.89 (-0.61%)
TSLA   172.49 (-1.21%)
NVDA   889.35 (-1.86%)
AMD   163.50 (-4.11%)
NIO   4.26 (-4.48%)
BABA   72.65 (-2.94%)
T   16.44 (+0.12%)
F   12.86 (-1.38%)
MU   124.65 (-2.24%)
GE   155.82 (-1.00%)
CGC   8.36 (+2.58%)
DIS   115.99 (-0.99%)
AMC   2.75 (-1.79%)
PFE   26.30 (-0.15%)
PYPL   65.52 (-0.43%)
XOM   123.26 (+1.21%)
NASDAQ:QTRX

Quanterix (QTRX) Stock Price, News & Analysis

$19.47
-0.48 (-2.41%)
(As of 09:40 AM ET)
Today's Range
$19.36
$19.71
50-Day Range
$19.95
$28.28
52-Week Range
$11.39
$29.70
Volume
25,908 shs
Average Volume
328,402 shs
Market Capitalization
$741.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

Quanterix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.17 Rating Score
Upside/​Downside
60.4% Upside
$32.00 Price Target
Short Interest
Healthy
2.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.18mentions of Quanterix in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$60,025 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.04) to ($1.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

1099th out of 2,784 stocks

Analytical Instruments Industry

40th out of 84 stocks

QTRX stock logo

About Quanterix Stock (NASDAQ:QTRX)

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

QTRX Stock Price History

QTRX Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
QTRX Apr 2024 22.500 call
QTRX Apr 2024 27.500 put
CryoPort Q4 2023 Earnings Preview
Quanterix price target raised by $2 at Scotiabank, here's why
Earnings Preview: Quanterix
See More Headlines
Receive QTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/12/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:QTRX
Fax
N/A
Employees
441
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$34.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+60.4%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-32,330,000.00
Pretax Margin
-25.84%

Debt

Sales & Book Value

Annual Sales
$122.37 million
Book Value
$9.17 per share

Miscellaneous

Free Float
35,476,000
Market Cap
$759.30 million
Optionable
Optionable
Beta
1.30
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Masoud Toloue Ph.D. (Age 43)
    President, CEO & Director
    Comp: $957.03k
  • Dr. David R. Walt Ph.D. (Age 71)
    Co-Founder, Chairman of Scientific Advisory Board & Independent Director
    Comp: $47.25k
  • Dr. Mark T. Roskey Ph.D. (Age 64)
    Senior Vice President of Strategic Partnerships
    Comp: $495.03k
  • Mr. Michael A. Doyle (Age 68)
    Executive Director of Finance
    Comp: $570.14k
  • Ms. Vandana Sriram CPA (Age 50)
    Chief Financial Officer
  • Mr. Daniel Pikora (Age 48)
    Chief Operating Officer
  • Dr. David C. Duffy Ph.D. (Age 53)
    Senior VP of Research & Development and CTO
    Comp: $299.05k
  • Ms. Alexandra Phillips
    Senior VP & Chief Information Officer
  • Ms. Laurie A. Churchill (Age 53)
    Senior VP, General Counsel & Secretary
  • David Panzerella
    Vice President of Sales

QTRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Quanterix stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" QTRX shares.
View QTRX analyst ratings
or view top-rated stocks.

What is Quanterix's stock price target for 2024?

6 equities research analysts have issued twelve-month price objectives for Quanterix's stock. Their QTRX share price targets range from $30.00 to $34.00. On average, they anticipate the company's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 60.4% from the stock's current price.
View analysts price targets for QTRX
or view top-rated stocks among Wall Street analysts.

How have QTRX shares performed in 2024?

Quanterix's stock was trading at $27.34 at the start of the year. Since then, QTRX shares have decreased by 27.0% and is now trading at $19.95.
View the best growth stocks for 2024 here
.

Are investors shorting Quanterix?

Quanterix saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,000,000 shares, a decrease of 18.7% from the March 15th total of 1,230,000 shares. Based on an average daily trading volume, of 334,600 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.9% of the shares of the stock are short sold.
View Quanterix's Short Interest
.

When is Quanterix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our QTRX earnings forecast
.

How were Quanterix's earnings last quarter?

Quanterix Co. (NASDAQ:QTRX) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.05. The company had revenue of $31.55 million for the quarter, compared to analysts' expectations of $27.92 million. Quanterix had a negative net margin of 26.42% and a negative trailing twelve-month return on equity of 9.15%.

What guidance has Quanterix issued on next quarter's earnings?

Quanterix updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $139.0 million-$144.0 million, compared to the consensus revenue estimate of $138.2 million.

What is Kevin Hrusovsky's approval rating as Quanterix's CEO?

15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees.

What other stocks do shareholders of Quanterix own?
When did Quanterix IPO?

Quanterix (QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Who are Quanterix's major shareholders?

Quanterix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Laurie J Olson, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Masoud Toloue, Michael A Doyle and William P Donnelly.
View institutional ownership trends
.

How do I buy shares of Quanterix?

Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QTRX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners